All In Biotech

Drug Trial Radar · NCT04810533

The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers

A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Mar 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

May 13, 2020

Primary completion

Mar 5, 2021

Study completion Mar 5, 2021

Sponsor

Sponsor type
Industry
First posted
Mar 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of \[14C\] SH-1028 in healthy Chinese male subjects. The study will be conducted into two steps:Firstly, 2 subjects are enrolled in to participate in the pilot study to grope for the collection time of plasma, urine and feces sampling post-dose. Then, the collection time of blood and excreta samples (urine and feces) from the subsequent 2-4 subjects will be adjusted according to the pilot study.

Conditions

  • Healthy Male Volunteers

Interventions

  • [14C] SH-1028Drug

    Volunteer will receive a single oral dose of 200 mg/88 uCi \[14C\]SH-1028 as a solution on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of radioactive dose of [14C] radiolabelled SH-1028 recovered in blood and in total, up to Day 15Time frame: Blood samples : - 0.5hrs, 1hrs, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs, 120hrs, 168hrs, 216hrs, 264hrs and 336hrs
  2. The percentage of radioactive dose of [14C] radiolabelled SH-1028 recovered in urine, faeces and in total, up to Day 15.Time frame: Day1 to Day 15
  3. The concentrations of SH-1028, Imp2 and Imp3 in plasma up to Day 15Time frame: Blood samples : - 0.5hrs, 1hrs, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs, 120hrs, 168hrs, 216hrs, 264hrs and 336hrs
  4. Proportion of different metabolitesTime frame: Blood samples : - 0.5hrs, 1hrs, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs, 120hrs, 168hrs, 216hrs, 264hrs and 336hrs
  5. Types of adverse eventsTime frame: Baseline (Day-2) to Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.